SARS-CoV-2 virus neutralizing antibodies and uses thereof

A sars-cov-2, antibody technology, applied in the direction of antibodies, antiviral agents, antiviral immunoglobulin, etc., can solve the problem of no treatment for SARS-CoV-2 coronavirus, and achieve the effect of reducing immunogenicity

Pending Publication Date: 2022-03-01
AMPSOURCE BIOPHARMA (SHANGHAI) INC
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] There is currently no specific drug to treat the SARS-CoV-2 coronavirus, and vaccines and neutralizing antibodies seem to be the most promising drugs for success

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • SARS-CoV-2 virus neutralizing antibodies and uses thereof
  • SARS-CoV-2 virus neutralizing antibodies and uses thereof
  • SARS-CoV-2 virus neutralizing antibodies and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0073] Before the present invention is described in detail below, it is to be understood that this invention is not limited to the particular methodology, protocols and reagents described herein. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the invention, which will be limited only by the appended claims. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0074] Abbreviations and Definitions

[0075] CDR Complementarity-Determining Region, the complementarity-determining region in the variable region of an immunoglobulin, delimited by the Kabat, IMGT, Chothia or AbM numbering system (see term "hypervariable region" or "CDR region" or "complementarity-determining region").

[0076] EC 50 Concentration that produces 50% ef...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the field of therapeutic antibodies and molecular immunology, and particularly provides an antibody aiming at SARS-CoV-2 coronavirus S protein and application of the antibody in preparation of a medicine for treating novel coronavirus pneumonia COVID-19. The antibody can specifically recognize and bind to SARS-CoV-2 coronavirus S protein with high affinity, which ensures that the antibody can block infection of SARS-CoV-2 to human cells.

Description

technical field [0001] The present invention relates to the field of therapeutic antibody and molecular immunology, more specifically, relates to a recombinant monoclonal antibody of SARS-CoV-2 coronavirus S protein, and the application of this antibody, especially in the treatment, prevention and diagnosis by Use in COVID-19 disease caused by SARS-CoV-2. Background technique [0002] As a newly emerged human pathogen, the novel coronavirus SARS-CoV-2 can cause severe respiratory disease and COVID-19 pneumonia with fever, fatigue, and dry cough as the main manifestations. According to data from the World Health Organization on August 19, 2020, there were 21,756,357 confirmed cases worldwide, resulting in 771,635 deaths. Based on the genome nucleic acid sequence, the new pathogen was proved to be a new member of the genus Betacoronavirus. The genome sequence similarity between SARS-CoV-2 and bat coronavirus RaTG13 is 96.2% (Zhou P et al, 2020, Nature, 579:270-273), and two ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/10C12N15/13A61K39/42A61P31/14A61P11/00G01N33/569G01N33/577
CPCC07K16/10A61P31/14A61P11/00G01N33/56983G01N33/577C07K2317/565C07K2317/56C07K2317/52C07K2317/76C07K2317/92C07K2317/33C07K2317/24G01N2333/165G01N2469/10
Inventor 李强孙见宇武翠张晓峰刁家升周利马心鲁
Owner AMPSOURCE BIOPHARMA (SHANGHAI) INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap